Illumina (NASDAQ:ILMN) SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $267.71, for a total transaction of $2,677,100.00. Following the completion of the transaction, the senior vice president now owns 80,996 shares in the company, valued at approximately $21,683,439.16. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Illumina opened at $269.67 on Friday, according to Marketbeat. Illumina has a 52 week low of $167.98 and a 52 week high of $272.90. The stock has a market cap of $39.46 billion, a PE ratio of 67.42, a price-to-earnings-growth ratio of 2.76 and a beta of 0.86. The company has a quick ratio of 2.41, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.43. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The firm had revenue of $782.00 million during the quarter, compared to analyst estimates of $744.30 million. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 30.8% compared to the same quarter last year. sell-side analysts forecast that Illumina will post 4.87 EPS for the current fiscal year.
A number of equities analysts have weighed in on ILMN shares. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a research report on Monday, April 16th. ValuEngine raised Illumina from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, March 10th. Citigroup raised Illumina from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $260.00 to $275.00 in a research report on Monday, February 5th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $265.00 target price (up previously from $255.00) on shares of Illumina in a research report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, five have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $251.14.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Nisa Investment Advisors LLC increased its position in shares of Illumina by 3.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 13,790 shares of the life sciences company’s stock valued at $3,013,000 after purchasing an additional 500 shares during the last quarter. Bank of Montreal Can increased its holdings in Illumina by 23.5% in the 4th quarter. Bank of Montreal Can now owns 105,906 shares of the life sciences company’s stock worth $23,139,000 after acquiring an additional 20,175 shares in the last quarter. National Pension Service increased its holdings in Illumina by 1.2% in the 4th quarter. National Pension Service now owns 137,418 shares of the life sciences company’s stock worth $30,024,000 after acquiring an additional 1,693 shares in the last quarter. Gateway Investment Advisers LLC increased its holdings in Illumina by 3.5% in the 4th quarter. Gateway Investment Advisers LLC now owns 95,711 shares of the life sciences company’s stock worth $20,912,000 after acquiring an additional 3,202 shares in the last quarter. Finally, Creative Planning increased its holdings in Illumina by 9.8% in the 4th quarter. Creative Planning now owns 12,384 shares of the life sciences company’s stock worth $2,706,000 after acquiring an additional 1,107 shares in the last quarter. 91.59% of the stock is owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.